Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
Last trade$32.36
Day change-$0.32 (-0.98%)
Day range$30.69 – $33.15
Volume134,991
Market cap$1.49B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for KRSA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for KRSA.
Recent news
Company coverage with links to the original publishers.
Tenet Healthcare is projected to report Q3 2026 earnings of $4.60 per share (up 24.3% YoY) on revenues of $5.47 billion (up 3.5% YoY). The company's Ambulatory Care segment is expected to drive growth with 8.4% revenue increase and 9.3% adjusted EBITDA growth. However, hospital patient days may decline 3.7% with increased utilization costs partially offsetting gains. The stock has an Earnings ESP of +11.11% and Zacks Rank #3, suggesting a likely earnings beat.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.